CBER Expands Post-Market Vaccine Safety Surveillance Portfolio Across COVID-19, RSV, and Influenza Programs

CBER's publicly catalogued assessments now span more than two dozen discrete post-market surveillance protocols, signalling to vaccine manufacturers that pharmacovigilance obligations under biologics licensure are being operationalised with increasing methodological rigour and real-world data depth.

The portfolio covers COVID-19 mRNA vaccines, seasonal influenza products, RSV vaccines for adults 60 years and older, and mpox prevention vaccines. Protocols range from active monitoring master frameworks to targeted signal investigations, including a 2023 seizure safety signal evaluation in children aged 2 to 4/5 years following COVID-19 mRNA vaccination, and a comparative myocarditis/pericarditis risk assessment published in December 2021. The breadth reflects CBER's application of multiple data sources: Medicare administrative claims, electronic health records, immunisation information systems, and university health system datasets.

For regulatory affairs leads, the methodological evolution is the more consequential development. The November 2025 publication on the double negative control method for unmeasured confounding, part of the PDUFA VII Methodology Development Project, indicates that CBER is actively refining the analytical standards against which post-approval effectiveness and safety data will be evaluated. Manufacturers whose pharmacovigilance plans rely on conventional observational designs should assess alignment with these emerging methods ahead of any supplemental BLA submissions or label update negotiations.

QA directors and regulatory leads at vaccine manufacturers should also note the structured use of master protocols across multiple vaccine classes. The COVID-19 Active Monitoring Master Protocol (March 2023), the influenza master protocol covering nine safety outcomes for the 2023-2024 season, and the mpox active monitoring framework each establish a replicable surveillance architecture. That architecture sets an implicit benchmark for the level of post-market evidence generation CBER expects from licence holders operating under 21 CFR Part 600 biologics requirements.

CBER also regulates three categories of licensed allergenic products, allergen extracts, allergen patch tests, and antigen skin tests, though the current assessment catalogue is concentrated on vaccine safety and effectiveness, with no allergenics-specific protocols listed in the most recent update cycle.

The continued publication of protocol addenda, such as the July 2024 MIS-C algorithm validation update, confirms that CBER treats its surveillance frameworks as living documents subject to revision as real-world data accumulates, a posture that manufacturers should factor into their own signal detection and CAPA documentation timelines.

The PDUFA VII methodology project outcome, expected to inform future guidance, represents the nearest measurable checkpoint for manufacturers recalibrating their post-market surveillance strategies.

Source: FDA CBER via What's New Vaccines Blood Biologics RSS Feed, 22 June 2026.